Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2008

View Archived Issues

Characterization of gene expression after ABR-215757 therapy in systemic lupus erythematosus

Dose escalation continues in phase II study of voreloxin in platinum-resistant ovarian cancer

TRU-015 retreatment well tolerated, maintains responses in rheumatoid arthritis patients

3SBio files for SFDA approval of NuLeusin in China

Telik enters discovery agreement for musculoskeletal and autoimmune diseases

Avastin provides an additional 4 months of life in patients with lung cancer

Chelsea commences phase I clinical trial of CH-4051

CVBT collaborates with Cardio Neo-Genesis for coronary heart disease candidate

FDA approves low-dose Premarin regimen to treat postmenopausal dyspareunia

Genentech licenses Ex-U.S. rights to GDC-0449 to Roche

DPD-207 active against Staphylococcus aureus in murine infection model

XF-73 activity, resistance examined in Staphylococcus aureus studies

Phase I results confirm tolerability, immunogenicity of cytomegalovirus vaccine

DSTL to evaluate Novacta's lantibiotics as broad-spectrum antiviral treatment

Antigen-pulsed dendritic cell-based vaccine feasible and safe in glioblastoma patients

Antitope and Isu Abxis sign research collaboration in therapeutic monoclonal antibodies

Lexicon announces completion of phase Ib trial of LX-1032 for carcinoid syndrome

Affymax completes enrollment in EMERALD 1 phase III clinical trial of Hematide

FDA designates as complete AMAG's resubmission for ferumoxytol NDA in CKD

Recent Ranbaxy patents disclose novel agents for inflammatory disorders

BioSeek licenses two antiinflammatory peptides from Amylin

IRM reports novel antiobesity compounds in a recent patent

New treatment strategies for transplant rejection described in recent patent lterature

ISTA files NDA with the FDA for Bepreve in allergic conjunctivitis ocular itching

NDA filed for Trelstar 6-month formulation for prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...